KCI Senior Leadership is composed of three scientific Associate Center Directors (ACDs) for Basic Sciences (Dr. Wei-Zen Wei), Clinical Sciences (Dr. Anthony Shields) and Population Sciences (Dr. Terrance Albrecht). A new senior leadership position, Scientific Director of Cores, has been added (Dr. Fred Miller) with responsibility for oversight and scientific leadership for the Cancer Center Cores. They are all supported by an ACD for Research Administration (Ms. Constance Claybaker) and overseen by the Deputy Center Director, Dr. Ann Schwartz. As President, CEO, and Center Director of the Karmanos Cancer Institute, Dr. Gerold Bepler bears ultimate responsibity for the administration and fiscal management of all KCI resources, including budgeting, personnel and faculty appointments, and space and equipment allocations. The primary responsibility of this team lies in ensuring that all of the Center's resources are optimally deployed to enhance the development of outstanding science as well as intra- and inter-programmatic interactions. These broad areas, each composed of more specific interests for investigation, define the role of the Senior Leaders to ensure the successful completion of broader scientific goals of the Institution through an active portfolio of individual Programs. The ACDs, by participating in such strategic committees as the ACD Committee, President's Committee, and Scientific Leadership Council, support ongoing discussions and debates about the allocation of resources. In addition, the scientific ACDs, oversee a discretionary fund of $750,000 annually to support pilot studies, the new post-doctoral program and recruitment opportunities during the year. Support is requested for Senior Leadership: Dr. Bepler (50% effort, 25% funding), Dr. A. Schwartz (25% effort, 10% funding), Dr. Wei (10% effort and funding), Dr. Shields (10% effort and funding), Dr. Albrecht (10% effort and funding), Ms. Claybaker (10% effort and funding) and Dr. F. Miller (25% effort and funding). Two of the scientific ACDs also serve as Program Leaders and funds for those efforts are requested elsewhere as is the funding for Ms. Claybaker as ACD of Research Administration.
Members of Senior Leadership oversee the mission and strategic plans for the KCI scientific community. The team ensures all KCI resources are optimally deployed to enhance the development of outstanding science.
|Ratanatharathorn, V; Deol, A; Ayash, L et al. (2015) Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT. Bone Marrow Transplant 50:106-12|
|Bollig-Fischer, Aliccia; Chen, Wei; Gadgeel, Shirish M et al. (2015) Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol 10:250-5|
|Motzer, Robert J; Rini, Brian I; McDermott, David F et al. (2015) Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 33:1430-7|
|Wijesinghe, Priyanga; Bepler, Gerold; Bollig-Fischer, Aliccia (2015) A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer. J Thorac Oncol 10:381-6|
|Koo, Imhoi; Wei, Xiaoli; Shi, Xue et al. (2014) Constructing Metabolic Association Networks Using High-dimensional Mass Spectrometry Data. Chemometr Intell Lab Syst 138:193-202|
|Koo, Imhoi; Yao, Sen; Zhang, Xiang et al. (2014) Comparative analysis of false discovery rate methods in constructing metabolic association networks. J Bioinform Comput Biol 12:1450018|
|Szalai, Gabor; Xu, Yi; Romero, Roberto et al. (2014) In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One 9:e110867|
|Heng, D Y C; Choueiri, T K; Rini, B I et al. (2014) Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 25:149-54|
|Speyer, Cecilia L; Hachem, Ali H; Assi, Ali A et al. (2014) Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer. PLoS One 9:e88830|
|Bengsch, F; Buck, A; Gunther, S C et al. (2014) Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene 33:4474-84|
Showing the most recent 10 out of 321 publications